Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer. by Liang, Ying et al.
UC Office of the President
Recent Work
Title
Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell 
Lung Cancer.
Permalink
https://escholarship.org/uc/item/6tc4c8rs
Journal
Clinical lung cancer, 16(5)
ISSN
1525-7304
Authors
Liang, Ying
Wakelee, Heather A
Neal, Joel W
Publication Date
2015-09-01
DOI
10.1016/j.cllc.2014.12.009
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Relationship of driver oncogenes to long term pemetrexed 
response in non-small cell lung cancer
Ying Liang1, Heather A. Wakelee2, and Joel W. Neal2
1Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory 
of Oncology in South China; and Collaborative Innovation Center for Cancer Medicine, 
Guangzhou, China
2Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, 
CA, USA
Abstract
Background—Pemetrexed is approved in the treatment of advanced stage non-squamous non-
small-cell lung cancer (NSCLC). The length of response is variable, and we thus sought to identify 
which clinicopathologic characteristics are associated with long term disease control with 
pemetrexed.
Methods—Patients with metastatic NSCLC were identified who received pemetrexed (with or 
without bevacizumab) for 12 months or longer, either as maintenance treatment after first-line 
platinum-based chemotherapy or as subsequent treatment. Clinical and pathological characteristics 
were collected.
Results—Of a total of 196 patients who received pemetrexed starting in 2007, 25 patients were 
identified who received pemetrexed for over one year. Of these, 15 patients received pemetrexed 
with or without bevacizumab as maintenance treatment and 10 patients received pemetrexed as 
subsequent treatment. Fifteen of the 25 patients (60%) had an oncogenic driver mutation as 
follows: five (20%) had ROS1 gene rearrangements, four (16%) had ALK gene rearrangements, 
three (12%) had KRAS mutations, two (8%) had epidermal growth factor receptor (EGFR) 
mutations, and one (4%) had an NRAS mutation. The median overall survival (OS) was 42.2 
months (95% confidence interval [CI]: 37.4–61.3) and median progression free survival (PFS) was 
22.1 months (95% CI: 15.1–29.1). Patients with an oncogenic driver mutation had significantly 
better PFS (p=0.006) and OS (p=0.001).
Conclusions—Among patients with NSCLC who received pemetrexed for an extended time, 
those with ALK and ROS1 gene rearrangements are proportionally overrepresented compared 
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with that anticipated in a general non-squamous NSCLC population, and patients with oncogenic 
driver mutations had improved outcomes.
Keywords
Non-small cell lung cancer; Pemetrexed; Driver oncogene; Anaplastic lymphoma kinase (ALK); 
ROS1; KRAS; NRAS; EGFR(Epidermal growth factor receptor)
INTRODUCTION
In the treatment of metastatic non–small-cell lung cancer (NSCLC), palliative chemotherapy 
has 1-year survival rates of 30% to 40%1,2. Historically, first line chemotherapy was 
administered for 3–4 months, followed by a period of observation given the limitations of 
cumulative drug toxicity. Pemetrexed is approved by the United States Food and Drug 
Administration (FDA) for treatment of patients with non-squamous NSCLC as single agent 
second-line treatment3, first-line treatment in combination with platinum2, and for 
maintenance therapy after first-line platinum-based chemotherapy4,5. Unlike most other 
cytotoxic chemotherapeutic agents used in NSCLC, pemetrexed is relatively well tolerated 
at full doses despite long term administration without a drug holiday.
Continuing pemetrexed as maintenance therapy either after first-line platinum or as 
monotherapy in subsequent treatment lines is increasingly common clinical practice. An 
overall survival (OS) and progression free survival benefit was established for maintenance 
pemetrexed after cisplatin therapy in the PARAMOUNT5 study, and the AVAPERL6 study 
demonstrated that maintenance pemetrexed and bevacizumab was superior to maintenance 
bevacizumab alone following cisplatin-based first line therapy.
In these trials, plus the JMEN4, PointBreak7 and JMEI3 trials of pemetrexed, some patients 
remained on pemetrexed based therapy without progression for more than 12 months, but 
the molecular characteristics of their tumors were not described. Since tumors are now 
routinely tested at least for epidermal growth factor receptor (EGFR) mutations and 
anaplastic lymphoma kinase (ALK) gene rearrangements, the interaction between these 
favorable driver oncogenes and duration of pemetrexed benefit is of clinical interest. Initial 
reports suggested that the progression free survival (PFS) on pemetrexed in metastatic 
NSCLC patients is significantly longer among those harboring ALK gene rearrangements 
than those without, with median PFS of about 9 months8, 9. In a subsequent modestly larger 
retrospective study10, the median PFS of patients with ALK positive tumors was more 
modest at 8.5 months when administered as a platinum-based doublet and 4.4 months as a 
single agent in the second and third line setting, as compared with KRAS which showed a 
relatively shorter median PFS of only 4.2 months as first line combination therapy, but 
longer 7.8 month PFS in the second and third line monotherapy setting. In phase III trials of 
1st line11 and 2nd line12 crizotinib studies versus chemotherapy in ALK arrangement NSCLC 
patients, pemetrexed had an intermediate PFS of 7.0 and 7.7 months, respectively. A recent 
case series from our institution suggested that some lung adenocarcinoma patients whose 
tumors harbored the ROS1 gene rearrangements also had a prolonged PFS when treated with 
pemetrexed.13 Interestingly, the outcomes of EGFR mutant patients have not been reported 
Liang et al. Page 2
Clin Lung Cancer. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
as an independent subgroup with regard to long-term pemetrexed therapy. Together, these 
prior studies suggested a potential interaction between pemetrexed response and molecular 
features of NSCLC. In the current retrospective study, patients were selected who were 
treated with pemetrexed for more than 12 months sequentially, with or without 
bevacizumab, to determine which clinicopathologic characteristics were associated with 
long term disease control.
PATIENTS AND METHODS
Patients
We identified patients with metastatic non-squamous NSCLC who received pemetrexed for 
12 months or more either as maintenance treatment after first-line platinum-based 
chemotherapy or as subsequent treatment at Stanford between 10/1/2007 to 05/30/2012 with 
the assistance of the Stanford Cancer Institute Research Database (SCIRDB) group. Stage 
was adjusted to conform to the 7th edition American Joint Committee on Cancer (AJCC)/
International Union Against Cancer (IUCC) staging system (the 2009 TNM Classification of 
Malignant Tumors)14. Clinical and pathological characteristics were collected using 
retrospective chart review. Adverse event (AE) information was retrospectively collected 
from the chart and classified according to the National Cancer Institute Common 
Terminology Criteria version 3.0. Patients were defined as “never-smoker” if they smoked 
≤100 cigarettes in their lifetime. This chart review protocol was approved by the Stanford 
Institutional Review Board.
Statistical Analyses
All statistical analyses were performed using SPSS (Solutions Statistical Package for the 
Social Sciences software), version 19.0 (IBM SPSS, Chicago, IL). To enrich for patients 
who had benefit from pemetrexed, the start date of pemetrexed was defined as the date of 
continuation or switch maintenance pemetrexed start (with or without bevacizumab) 
following completion of first-line platinum-based chemotherapy or from the initial 
administration date when given as a second-line or beyond treatment. PFS was taken as the 
interval from the date of pemetrexed initiation as maintenance therapy after first-line 
platinum-based chemotherapy or as a second-line or beyond treatment until first documented 
clinical or radiographic progression, escalation or change in therapy (“systemic 
progression”), or death from any cause, as described in Camidge et al8. OS was measured 
from the date of pemetrexed initiation as maintenance therapy after first-line platinum-based 
chemotherapy or as a second-line or beyond treatment to the date of death from any cause or 
was censored at the date of data cutoff (Jun. 30, 2014). Survival functions were estimated by 
Kaplan-Meier method and the log-rank test was used to compare the difference between two 
groups. Significance levels and estimates of hazard ratios (HRs) and their 95% confidence 
intervals (CIs) were calculated with a Cox proportional hazard model. Two-sided 
significance level was defined as P < 0.05.
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RESULTS
Patient Characteristics
From 10/1/2007 to 5/30/2012, a total of 196 advanced NSCLC patients received pemetrexed 
(either as a monotherapy or combined with bevacizumab) in maintenance therapy after first-
line platinum-based chemotherapy or as monotherapy in a second-line or beyond treatment. 
Among these 196 patients, 25 (12.8%) patients were identified for further description whose 
PFS of pemetrexed treatment was more than 12 months. Characteristics of the study patients 
were shown in Table 1, and notable for a predominance of women and never-smokers.
Treatment
Of the entire group of 25 identified patients, fifteen patients (60%) received pemetrexed 
with or without bevacizumab as maintenance treatment after first-line chemotherapy 
consisting of pemetrexed/platinum/bevacizumab in 8/25 patients (32%), paclitaxel/
carboplatin/bevacizumab in one patient (8%), and pemetrexed/platinum in 6/25 patients 
(24%). Of this group, 10/25 (40%) received pemetrexed and bevacizumab and 5/25 (20%) 
patients received pemetrexed alone. Nine of the initial 25 patients (36%) received 
pemetrexed monotherapy and one patient (4%) received pemetrexed and bevacizumab as 
second-line or beyond treatment. At the time of data cutoff, there were 7 and 2 patients in 
the maintenance therapy and second-line or beyond treatment groups, respectively, who 
were still continuing therapy. Six of the 25 patients (24%) developed brain metastases 
during treatment, and all continued to receive pemetrexed after local radiosurgical brain 
treatment of limited brain-only progression. These brain metastases developed at a median 
of 10.9 months into treatment (range: 2.6–25.4 months), then patients went on to continue 
pemetrexed for an additional median of 4.0 months (range 1.7–15.8) after CNS-only 
progression. All systemic progression events occurred while patients were still on 
pemetrexed. As of last follow-up date, 25 patients received a total of 755 cycles of treatment 
with a median number of cycles of 25 (range: 15–62). The 10 patients who had pemetrexed 
with bevacizumab as maintenance treatment after first-line chemotherapy received a median 
of 34 cycles of therapy [bevacizumab: median 23 (range, 3–27) cycles, pemetrexed: 34 
(range, 15–62) cycles]. Five patients discontinued bevacizumab (4 because of AE) and 3 
patients were still continuing pemetrexed and bevacizumab treatment at the cutoff date. 
Subsequent post-progression (PD) treatment included docetaxel, gemcitabine, erlotinib, 
crizotinib, other ALK inhibitors, and palliative radiotherapy.
Immunohistochemical Results and Molecular Analysis
Immunohistochemical testing performed by standard methodology on most tumors revealed 
positive results as follows: cytokeratin 7 (CK7) in 16/16, CK20 in 0/13, thyroid transcription 
factor 1(TTF-1) in 21/21. Molecular testing was also performed in most patients as follows: 
ALK status was determined using the standard break-apart ALK fluorescent in situ 
hybridization (FISH) assay15, ROS1 status was detected with break-apart FISH16, EGFR, 
KRAS, and other cancer-related genes using DNA sequencing (2007–2011) or SNaPshot 
(2011–2013)17. These results are shown in table 2. Twenty of twenty-five (80%) patients 
had at least one molecular test performed and 15/25 (60%) patients had an oncogenic driver 
mutation (Table 2 and Figure 1). Two of twenty-five (8%) patients who received EGFR 
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testing had L858R mutations. KRAS and NRAS mutation were found in 3/25(12%) and 1/25 
(4%) patients, respectively. ALK and ROS1 gene rearrangements were identified with FISH 
in 4/25 (16%) and 5/25(20%) patients, respectively. No other molecular alterations including 
BRAF, APC, CTNNB1, IDH1, IDH2, NOTCH1, PIK3CA, PTEN, P53 were found among 
patients. Five patients’ tumors were negative for molecular alterations following at least 
EGFR, KRAS, and ALK testing.
Efficacy
In the fifteen patients who received maintenance treatment following first-line 
chemotherapy, 6/15 (40%) patients achieved a partial response (PR) from the first-line 
platinum-base chemotherapy: among these 6 patients there were 4 patients who received 
pemetrexed/ platinum chemotherapy (2 patients received additional bevacizumab). There are 
1/10(10%) patients who achieved PR and 9/10 (90%) patients who achieved stable disease 
(SD) as best response during pemetrexed in second-line chemotherapy with no complete 
response (CR).
At the time of data cutoff, survival of all 25 patients was evaluated. After median follow-up 
time of 40.1 months (range, 38.2–62.5 months), the median PFS was 22.1 months (95% 
confidence interval [CI]: 15.1–29.1), the median overall survival time was 42.2 months 
(95% CI: 37.4–61.3) and 2-year and 3-year OS rates were 66.0% and 49.5%, respectively. 
(Figure 2A–B). The median survival time of first-line continuation or switch maintenance 
treatment and second-line/beyond chemotherapy was not reached vs. 23.0 months, 
respectively (p= 0.057). The PFS was not different between these two groups, with median 
PFS of 28.1 vs. 19.6 months (p=0.47). With respect to bevacizumab treatment in the 
maintenance setting, patients receiving pemetrexed and bevacizumab had improved OS 
(p=0.021) compared with patients receiving pemetrexed maintenance alone, but no 
difference was observed in PFS (p=0.251).
For the whole group, OS and PFS were not associated with sex, age, or smoking status 
(Table 3). However, patients with any identified oncogenic driver mutation had significantly 
better OS (p=0.001) and PFS (p=0.006) (Table 3 and Figure 2C–D). The OS and PFS of 
patients with different oncogenic driver mutation did not demonstrate a significant 
difference between the groups, though the numbers compared were small (Figure 2E–F).
Tolerability of long term pemetrexed administration
During treatment, most AEs were grade 1 or 2 and non-hematologic, with the most common 
being fatigue, nausea, and constipation (Table 4). There were 5 (20%) patients who 
experienced a grade 3 or 4 AE. All grade ≥3 toxicities were non-hematologic and occurred 
among patients receiving concurrent bevacizumab: one patient with grade 4 proteinuria and 
nephrotic syndrome, one patient with grade 3 left ventricular systolic dysfunction, and one 
patient with grade 3 pulmonary embolisms. There were 8 deaths at last follow-up and all of 
them attributed to tumor PD. No deaths appeared related to pemetrexed treatment.
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Discussion
In this landmark analysis, we selected patients who tolerated long term pemetrexed 
administration to evaluate their characteristics and tolerability of treatment. In our study, 25 
patients were selected from a population of 196 patients (12.8%) who received pemetrexed 
for more than 12 months (either as maintenance, or as second line therapy or beyond). This 
percentage was comparable to that identified in the PARAMOUNT trial5, on which 67 of 
359 (17.0%) patients were still on pemetrexed maintenance without progression at 12 
months, and the JMEN4 trial in which 27/326 (8.3%) of non-squamous patients remained on 
pemetrexed switch maintenance therapy for 12 months. However, in the JMEI second-line 
treatment trial3, there were only 2/283 (0.7%) patients still on pemetrexed second-line 
treatment without progression at 15 months.
We found that long term pemetrexed use was quite tolerable, with chronic side effects of 
edema and fatigue, which did not preclude continuation of therapy. Patients who received 
pemetrexed with bevacizumab as maintenance treatment had significantly better OS than 
those receiving pemetrexed monotherapy alone. While virtually all of the bevacizumab 
patients were continuing first line maintenance treatment, a large potential confounder, our 
data, as well as the conclusion from AVAPERL6 that pemetrexed plus bevacizumab 
maintenance is superior to bevacizumab alone, raises the question of whether maintenance 
pemetrexed plus bevacizumab is superior to pemetrexed alone. This is being addressed by 
the ongoing ECOG 5508 trial (NCT01107626) comparing maintenance therapy with 
bevacizumab, pemetrexed, or a combination of bevacizumab and pemetrexed following 4 
cycles of first line carboplatin/paclitaxel/bevacizumab chemotherapy, but it is unlikely that 
many patients with known EGFR, ALK, or ROS1 oncogenic driver mutations will 
participate in this trial.
Rationalizing that progression in the central nervous system (CNS) alone may reflects the 
failure of CNS penetration due to blood-brain barrier and that systemic disease may 
maintain sensitivity, we observed that a group of patients that developed brain metastatses 
had radiosurgical brain treatment then resumed pemetrexed for an additional median of 4.0 
months PFS. This strategy has been previously described in other studies of the efficacy of 
pemetrexed in ALK-positive patients8, 18, and is also a recommended practice guidelines 
option for patients with EGFR or ALK positive lung cancer receiving treatment with 
tyrosine kinase inhibitors. The prospective ASPIRATION trial20 also showed that 
continuing erlotinib beyond RECIST PD is feasible, with additional median PFS of 3.1 
months in post-PD erlotinib patients. In the present report, the additional PFS gained was 
only 4.0 months using this strategy in a selected population who had already received 
pemetrexed for more than 12 months, suggesting that the development of brain metastases 
often heralds the development of systemic resistance.
Limitations of our retrospective study included that survival numbers have little population 
meaning when selecting patients with a more favorable response, and bias related to single 
institution practice patterns. Additionally, there is bias in the molecular testing itself – our 
20% overall ROS1 positive rate (and greater than 70% of those tested) reflects that long term 
responders with no known oncogenic driver mutation were subjected to additional testing as 
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testing for new “actionable” drivers was performed to identify future effective treatments. 
Despite these limitations, we found that patients with any known oncogenic driver mutation 
did particularly well with maintenance pemetrexed. There were a disproportionately high 
number of patients with ALK and ROS1 rearrangements in our cohort, as well as some with 
KRAS mutations who did quite well over time. Interestingly, one patient with an NRAS-
mutant tumor received first line continuation pemetrexed and bevacizumab for over 40 
months. Of note, only two patients with EGFR mutant tumors were in the selected cohort, 
perhaps an underrepresentation of this population of patients related to use of EGFR targeted 
agents preferentially, or more interestingly suggesting less inherent sensitivity of these 
tumors to pemetrexed. Overall, our cohort of patients with any oncogenic driver mutation 
had significantly better PFS and OS than molecular wild type or undetected patients, 
consistent with the recent Lung Cancer Mutational Consortium21 results. Interestingly, our 
PFS findings in particular did not depend on receipt of a tyrosine kinase inhibitor therapy for 
an actionable driver. Since most patients with targeted alterations still receive chemotherapy 
at some point, patients with known ALK or ROS1 alterations could be prioritized for a 
pemetrexed containing regimen, and patients with KRAS and NRAS alterations without 
targeted options could reasonably receive first line pemetrexed based therapy. This work 
also demonstrates an apparent sensitivity of ROS1 NSCLC to pemetrexed treatment, as 
previously suggested by our group13.
In this era of molecular targeted therapies, conventional chemotherapy is still a standard 
treatment before or after the failure of targeted agents. By maintaining tolerable treatments, 
a subset of patients can achieve long term disease control even with conventional cytotoxic 
chemotherapy, suggesting that chemotherapy and targeted therapies are indeed 
complementary and work in concert to prolong both overall survival and quality of life.
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Clinical Practice Points
- Previous studies have shown that some patients may remain on maintenance 
pemetrexed therapy without progression or undue toxicity for extended 
durations.
- ALK and ROS1 rearranged NSCLC appear particularly sensitive to 
pemetrexed based treatment.
- Among patients who received more than 12 months of pemetrexed therapy, 
the majority had defined oncogenic driver mutations including EGFR, ALK, 
ROS1, and KRAS
- As a group, patients with oncogenic driver mutation positive NSCLC had 
significantly better progression free and overall survival than wild type and 
untested patients.
- Patients with known molecular driver positive non-squamous NSCLC should 
be prioritized to receive a pemetrexed based regimen, with maintenance 
pemetrexed therapy, in their course of treatment.
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Fig 1. 
Incidence of driver oncogene in the patients receiving pemetrexed with or without 
bevacizumab for 12 months or more as maintenance or second line/ beyond treatment.
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Fig 2. 
Overall survival (OS) and progression free survival (PFS) of patients receiving pemetrexed 
with or without bevacizumab for 12 months or more as maintenance or second line/ beyond 
treatment. (A) PFS of whole group; (B) OS of whole group;(C) Improved PFS of patients 
with tumors harboring identified oncogenic driver mutation (p=0.006); (D) Improved OS of 
patients with tumors harboring identified oncogenic driver mutation PFS (p=0.001); (E) PFS 
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of patients with different specific driver oncogenic mutations; (F) OS of patients with 
different specific driver oncogenic mutations.
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Table 1
Patient and Tumor Characteristics
Variable Patient
number
%
Gender
Male 7 28%
Female 18 72%
Age(year)
  Median 60
  range 19–82
  <60 years 12 48%
  ≥60 years 13 52%
Smoking status
  Former or current smoker 12 48%
  Never-smoker 13 52%
WHO performance status
    0 3 12%
    1 20 80%
    2 2 8%
Stage
Stage IV 20 80%
Recurrent/Metastatic 5 20%
Histology
Adenocarcinoma 23 92%
NSCLC, NOS 2 8%
Ethnics
Asian 7 28%
Non-Asian 18 72%
Site of metastasis
Pleural effusion 5 20%
Lung metastasis 14 56%
Adrenal metastasis 4 16%
Liver metastasis 4 15%
Bone metastasis 12 48%
Brain Metastasis 10 40%
Abbreviations: NSCLC, non–small-cell lung cancer; NOS, not otherwise specified;
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Table 3
Subgroup analysis of overall survival and progression-free survival
Variable
OS PFS
HR
(95%CI) P value
HR
(95%CI) P value
Sex
  M 1.014 (0.225–4.569) 0.986 0.768 (0.266–2.218) 0.624
  F
Age(year)
  <60 years 1.889 (0.437–8.163) 0.176 1.998 (0.719–5.551) 0.387
  ≥60 years
Smoking status
  Former/current smoker 3.477 (0.681–17.749) 0.113 1.020 (0.382–2.757) 0.969
  Non-smoker
Oncogenic driver mutation
  Yes 10.743 (2.050–56.306) 0.001 4.296 (1.399–13.193) 0.006
  No
OS, overall survival; PFS, progression-free survival; HR, hazard Ratio; CI, confidence interval
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